NCT00004866CompletedPhase 2
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Daiichi Sankyo
- Locations
- 11
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or recurrent cancer of the cervix.
Detailed Description
OBJECTIVES:
- Determine the antitumor activity of DX-8951f in women with advanced or recurrent squamous cell carcinoma of the cervix.
- Evaluate the quantitative and qualitative toxic effects of this regimen in these patients.
- Evaluate the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive DX-8951f IV over 30 minutes daily for 5 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months until death.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 2
Chemotherapy in Treating Women With Metastatic Breast CancerBreast CancerNCT00004046Daiichi Sankyo
Completed
Phase 2
DX-8951f in Treating Patients With Liver CancerLiver CancerNCT00004108Daiichi Sankyo
Completed
Phase 2
DX-8951f in Treating Patients With Biliary CancerExtrahepatic Bile Duct CancerGallbladder CancerLiver CancerNCT00005938Daiichi Sankyo
Completed
Phase 2
DX-8951f in Treating Patients With Metastatic Cancer of the PancreasPancreatic CancerNCT00003951Daiichi Sankyo37
Completed
Phase 2
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerLung CancerNCT00005091Daiichi Pharmaceuticals